0001209191-18-019635.txt : 20180314
0001209191-18-019635.hdr.sgml : 20180314
20180314171621
ACCESSION NUMBER: 0001209191-18-019635
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180312
FILED AS OF DATE: 20180314
DATE AS OF CHANGE: 20180314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Culwell Kelly
CENTRAL INDEX KEY: 0001726183
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36754
FILM NUMBER: 18690270
MAIL ADDRESS:
STREET 1: C/O EVOFEM BIOSCIENCES, INC.
STREET 2: 12400 HIGH BLUFF DRIVE, SUITE 600
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Evofem Biosciences, Inc.
CENTRAL INDEX KEY: 0001618835
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208527075
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12400 HIGH BLUFF DRIVE
STREET 2: SUITE 600
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 550-1900
MAIL ADDRESS:
STREET 1: 12400 HIGH BLUFF DRIVE
STREET 2: SUITE 600
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Neothetics, Inc.
DATE OF NAME CHANGE: 20140905
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-12
0
0001618835
Evofem Biosciences, Inc.
EVFM
0001726183
Culwell Kelly
C/O EVOFEM BIOSCIENCES, INC.
12400 HIGH BLUFF DRIVE, SUITE 600
SAN DIEGO
CA
92130
0
1
0
0
Chief Medical Officer
Stock option (right to buy)
7.29
2018-03-12
4
A
0
260000
0.00
A
2028-03-12
Common Stock
260000
260000
D
Dr. Culwell acquired a vested interest in 66.67% of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018 (the "Vesting Start Date"). The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from the Vesting Start Date. The option was awarded in connection with Dr. Culwell's service as Chief Medical Officer.
The option was granted subject to stockholder approval and will be forfeited if stockholder approval is not obtained within twelve months of the date of grant.
/s/ Melanie Ruthrauff Levy, attorney-in-fact
2018-03-14